<?xml version="1.0" ?>
<text author="Bruno Bujoli, Jean-Claude Scimeca, Elise Verron" dateCollected="2019-11-03" id="amalgum_academic_doc473" shortTile="fibrin-multipurpose" sourceURL="https://www.mdpi.com/1999-4923/11/11/556/htm" speakerCount="0" speakerList="none" title="Fibrin as a Multipurpose Physiological Platform for Bone Tissue Engineering and Targeted Delivery of Bioactive Compounds" type="academic">
<head>
<s type="decl">
5.	LS	@ord@
Fibrin	NNP	Fibrin
Handling	VBG	handle
for	IN	for
Bioactive	JJ	bioactive
Compounds	NNS	Compound
Delivery	NN	Delivery
</s>
</head>
<head>
<s type="frag">
5.1	CD	@card@
.	.	.
</s>
<s type="ger">
Tuning	VBG	Tuning
Fibrin	NNP	Fibrin
Intrinsic	NNP	Intrinsic
Characteristics	NNS	Characterictics
</s>
</head>
<p>
<s type="decl">
Bioactive	JJ	bioactive
compounds	NNS	compound
including	VBG	include
growth	NN	growth
factors	NNS	factor
,	,	,
cytokines	NNS	cytokine
,	,	,
drugs	NNS	drug
,	,	,
and	CC	and
nucleic	NN	nucleic
acids	NNS	acid
can	MD	can
be	VB	be
easily	RB	easily
entrapped	VBN	entrapped
in	IN	in
the	DT	the
fibrin	NN	fibrin
matrix	NN	matrix
by	IN	by
mixing	VBG	mix
them	PRP	them
with	IN	with
fibrinogen	NN	fibrinogen
or	CC	or
thrombin	NN	thrombin
.	.	.
</s>
<s type="decl">
In	IN	in
general	NN	general
,	,	,
fibrin	NN	fibrin
matrix	NN	matrix
remains	VBZ	remain
porous	JJ	porous
regardless	RB	regardless
the	DT	the
conditions	NNS	condition
and/or	IN	and/or
thrombin	NN	thrombin
and	CC	and
fibrinogen	NN	fibrinogen
ratios	NNS	ratio
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
increasing	VBG	increase
fibrinogen	NN	fibrinogen
and/or	CC	and/or
thrombin	NN	thrombin
concentrations	NNS	concentration
densifies	VBZ	densify
the	DT	the
structure	NN	structure
of	IN	of
a	DT	a
fibrin	NN	fibrin
gel	NN	gel
and	CC	and
reduces	VBZ	reduce
its	PRP$	its
degradation	NN	degradation
rate	NN	rate
,	,	,
thus	RB	thus
slowing	VBG	slow
down	RP	down
the	DT	the
diffusion	NN	diffusion
of	IN	of
loaded	VBN	load
molecules	NNS	molecule
(	-LRB-	(
e.	NNP	e.
g.	NNP	g.
,	,	,
FGF	NNP	FGF
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
release	NN	release
profile	NN	profile
of	IN	of
active	JJ	active
compounds	NNS	compound
is	VBZ	be
affected	VBN	affect
by	IN	by
their	PRP$	their
physicochemical	JJ	physicochemical
properties	NNS	property
including	VBG	include
partition	NN	partition
coefficient	NN	coefficient
,	,	,
size	NN	size
and	CC	and
functional	JJ	functional
groups	NNS	group
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
hydrophilic	JJ	hydrophilic
molecules	NNS	molecule
readily	RB	readily
leach	VBP	leach
out	RP	out
(	-LRB-	(
e.	FW	e.
g.	FW	g.
,	,	,
erythromycin	NN	erythromycin
,	,	,
mitomycin	FW	mitomycin
C	NNP	C
,	,	,
fluorouracil	NN	fluorouracil
etc.	FW	etc.
)	-RRB-	)
,	,	,
while	IN	while
hydrophobic	JJ	hydrophobic
molecules	NNS	molecule
,	,	,
or	CC	or
those	DT	those
which	WDT	which
display	VBP	display
a	DT	a
strong	JJ	strong
chemical	JJ	chemical
affinity	NN	affinity
for	IN	for
the	DT	the
matrix	NN	matrix
components	NNS	component
,	,	,
are	VBP	be
released	VBN	release
more	RBR	more
gradually	RB	gradually
(	-LRB-	(
e.	NNP	e.
g.	FW	g.
,	,	,
streptomycin	NN	streptomycin
,	,	,
sulfamethoxazole-trimethoprim	NN	sulfamethoxazole-trimethoprim
,	,	,
cefazolin	NN	cefazolin
,	,	,
enocitabine	NN	enocitabine
etc.	FW	etc.
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
some	DT	some
compounds	NNS	compound
need	VBP	need
to	TO	to
be	VB	be
modified	VBN	modify
chemically	RB	chemically
to	TO	to
become	VB	become
more	RBR	more
hydrophobic	JJ	hydrophobic
,	,	,
resulting	VBG	result
in	IN	in
a	DT	a
prolonged	VBN	prolong
retention	NN	retention
within	IN	within
the	DT	the
matrix	NN	matrix
.	.	.
</s>
<s type="sub">
Conversely	RB	Conversely
,	,	,
a	DT	a
proteolytic	JJ	proteolytic
degradation	NN	degradation
may	MD	may
be	VB	be
required	VBN	require
to	TO	to
speed	VB	speed
up	RP	up
the	DT	the
diffusion	NN	diffusion
process	NN	process
.	.	.
</s>
</p>
<p>
<s type="decl">
Lastly	RB	lastly
,	,	,
fibrin	NN	fibrin
matrix	NN	matrix
proteolysis	NN	proteolysis
through	IN	through
the	DT	the
action	NN	action
of	IN	of
thrombin	NN	thrombin
or	CC	or
plasmin	NN	plasmin
induces	VBZ	induce
the	DT	the
release	NN	release
of	IN	of
entrapped	VBN	entrapped
compounds	NNS	compound
.	.	.
</s>
<s type="decl">
In	IN	in
order	NN	order
to	TO	to
restrict	VB	restrict
this	DT	this
breakdown	NN	breakdown
of	IN	of
the	DT	the
matrix	NN	matrix
,	,	,
the	DT	the
co-entrapment	NN	co-entrapment
of	IN	of
proteolysis	NN	proteolysis
inhibitors	NNS	inhibitor
(	-LRB-	(
aprotinin	NN	aprotinin
,	,	,
matrix	NN	matrix
metalloproteinases	NNS	metalloproteinase
inhibitors	NNS	inhibitor
such	JJ	such
as	IN	as
galardin	NN	galardin
)	-RRB-	)
was	VBD	be
investigated	VBN	investigate
.	.	.
Ahmed	NNP	Ahmed
et	FW	et
al.	FW	al.
identified	VBN	identify
in	IN	in
their	PRP$	their
model	NN	model
(	-LRB-	(
i.	FW	i.
e.	FW	e.
,	,	,
chondroprogenitor	JJ	chondroprogenitor
clonal	JJ	clonal
cell	NN	cell
line	NN	line
)	-RRB-	)
the	DT	the
enzymes	NNS	enzyme
responsible	JJ	responsible
for	IN	for
fibrin	NN	fibrin
gel	NN	gel
breakdown	NN	breakdown
.	.	.
</s>
<s type="decl">
It	PRP	it
appeared	VBD	appear
that	DT	that
metalloproteinases	NNS	metalloproteinase
(	-LRB-	(
MMP-2	NNP	MMP-2
,	,	,
MMP-3	NNP	MMP-3
,	,	,
MMP-9	NNP	MMP-9
)	-RRB-	)
were	VBD	be
secreted	VBN	secrete
concomitantly	RB	concomitantly
with	IN	with
fibrin	NN	fibrin
hydrogels	NNS	hydrogel
breakdown	NN	breakdown
.	.	.
</s>
<s type="decl">
They	PRP	they
also	RB	also
noted	VBD	note
high	JJ	high
plasmin	NN	plasmin
activity	NN	activity
in	IN	in
the	DT	the
conditioned	JJ	condition
media	NN	media
during	IN	during
hydrogel	NN	hydrogel
breakdown	NN	breakdown
.	.	.
</s>
<s type="decl">
Then	RB	then
,	,	,
they	PRP	they
demonstrated	VBD	demonstrate
that	IN	that
aprotinin	NN	aprotinin
and	CC	and
galardin	NN	galardin
,	,	,
in	IN	in
combination	NN	combination
or	CC	or
separately	RB	separately
,	,	,
prevented	VBN	prevent
fibrin	NN	fibrin
hydrogels	NNS	hydrogel
degradation	NN	degradation
.	.	.
</s>
<figure>
<s type="frag">
Figure	NN	Figure
4	CD	4
</s>
</figure>
<s type="decl">
summarizes	VBZ	summarize
the	DT	the
modifications	NNS	modification
which	WDT	which
can	MD	can
be	VB	be
made	VBN	make
on	IN	on
fibrin	NN	fibrin
matrix	NN	matrix
to	TO	to
regulate	VB	regulate
the	DT	the
release	NN	release
of	IN	of
entrapped	VBN	entrapped
agents	NNS	agent
.	.	.
</s>
</p>
<head>
<s type="frag">
5.2	CD	@card@
.	.	.
</s>
<s type="decl">
Modifying	VBG	modify
Fibrin	NNP	Fibrin
and/or	VBZ	and/or
Active	JJ	Active
Agents	NNS	agent
for	IN	for
Efficient	JJ	Efficient
Combination	NN	Combination
and	CC	and
Delivery	NN	Delivery
</s>
</head>
<p>
<s type="decl">
In	IN	in
some	DT	some
instances	NNS	instance
,	,	,
fibrin	NN	fibrin
exhibits	VBZ	exhibit
innate	JJ	innate
affinity	NN	affinity
for	IN	for
therapeutics	NNS	therapeutics
and	CC	and
growth	NN	growth
factors	NNS	factor
but	CC	but
in	IN	in
other	JJ	other
cases	NNS	case
,	,	,
the	DT	the
covalent	NN	covalent
attachment	NN	attachment
of	IN	of
these	DT	these
compounds	NNS	compound
to	TO	to
fibrin	NN	fibrin
is	VBZ	be
considered	VBN	consider
.	.	.
</s>
<s type="decl">
This	DT	this
generally	RB	generally
requires	VBZ	require
chemical	JJ	chemical
modifications	NNS	modification
with	IN	with
reactive	JJ	reactive
functional	JJ	functional
groups	NNS	group
(	-LRB-	(
thiols	NNS	thiol
,	,	,
azides	NNS	azide
)	-RRB-	)
allowing	VBG	allow
a	DT	a
stable	JJ	stable
association	NN	association
.	.	.
</s>
<s type="decl">
Then	RB	then
,	,	,
reduction/hydrolysis	JJ	reduction/hydrolysis
reactions	NNS	reaction
or	CC	or
enzymatic	NN	enzymatic
cleavage	NN	cleavage
mediate	VBP	mediate
the	DT	the
release	NN	release
of	IN	of
active	JJ	active
molecules	NNS	molecule
.	.	.
</s>
<s type="decl">
It	PRP	it
was	VBD	be
shown	VBN	show
that	IN	that
this	DT	this
approach	NN	approach
prolongs	VBZ	prolong
the	DT	the
delivery	NN	delivery
phase	NN	phase
of	IN	of
growth	NN	growth
factors	NNS	factor
for	IN	for
example	NN	example
.	.	.
</s>
</p>
<p>
<s type="decl">
As	IN	as
another	DT	another
illustration	NN	illustration
,	,	,
covalently	JJ	covalently
binding	NN	binding
of	IN	of
BMP	NNP	BMP
and	CC	and
RGD	NNP	RGD
sequences	NNS	sequence
to	TO	to
fibrin	NN	fibrin
allows	VBZ	allow
interactions	NNS	interaction
with	IN	with
bone	NN	bo
marrow	NN	marrow
stromal	NN	stromal
cells	NNS	cell
through	IN	through
integrin	NN	integrin
surface	NN	surface
receptors	NNS	receptor
that	WDT	that
triggered	VBD	triggered
downstream	NN	downstream
signaling	NN	signal
pathways	NNS	pathway
.	.	.
</s>
<s type="decl">
More	RBR	more
sophisticated	VBN	sophisticated
constructions	NNS	construction
have	VBP	have
been	VBN	be
tested	VBN	tested
.	.	.
</s>
<s type="imp">
Starting	VBG	start
from	IN	from
BMP-2	NNP	BMP-2
,	,	,
Schmoekel	NNP	Schmoekel
et	FW	et
al.	FW	al.
propose	VB	propose
a	DT	a
tripartite	JJ	tripartite
fusion	NN	fusion
protein	NN	protein
denoted	VBN	denote
as	IN	as
TG-pl-BMP-2	NNP	TG-pl-BMP-2
.	.	.
</s>
<s type="decl">
Under	IN	Under
the	DT	the
control	NN	control
of	IN	of
the	DT	the
blood	NN	blood
transglutaminase	NN	transglutaminase
factor	NN	factor
XIIIa	NNP	XIIIa
,	,	,
the	DT	the
N-terminal	NNP	N-terminal
transglutaminase	NN	transglutaminase
substrate	NN	substrate
domain	NN	domain
(	-LRB-	(
TG	NNP	TG
)	-RRB-	)
provides	VBZ	provide
a	DT	a
covalent	NN	covalent
attachment	NN	attachment
to	TO	to
fibrin	NN	fibrin
during	IN	during
coagulation	NN	coagulation
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
upon	IN	upon
the	DT	the
action	NN	action
of	IN	of
cell-activated	JJ	cell-activated
plasmin	NN	plasmin
,	,	,
the	DT	the
central	JJ	central
plasmin	NN	plasmin
substrate	NN	substrate
domain	NN	domain
(	-LRB-	(
pl	NN	pl
)	-RRB-	)
gives	VBZ	give
a	DT	a
cleavage	NN	cleavage
site	NN	site
for	IN	for
the	DT	the
local	JJ	local
release	NN	release
of	IN	of
the	DT	the
attached	VBN	attach
growth	NN	growth
factor	NN	factor
from	IN	from
the	DT	the
fibrin	NN	fibrin
matrix	NN	matrix
.	.	.
</s>
<s type="decl">
Lastly	RB	lastly
,	,	,
the	DT	the
C-terminal	NNP	C-terminal
human	JJ	human
BMP-2	NNP	BMP-2
domain	NN	domain
displays	VBZ	display
an	DT	an
osteogenic	JJ	osteogenic
activity	NN	activity
.	.	.
</s>
</p>
<p>
<s type="sub">
As	IN	as
an	DT	an
alternative	NN	alternative
to	TO	to
active	JJ	active
molecules	NNS	molecule
derivatization	NN	derivatization
,	,	,
fibrin	NN	fibrin
functionalization	NN	functionalization
can	MD	can
also	RB	also
be	VB	be
achieved	VBN	achieve
.	.	.
</s>
<s type="inf">
For	IN	for
example	NN	example
,	,	,
to	TO	to
facilitate	VB	facilitate
BMP	JJ	BMP
interaction	NN	interaction
with	IN	with
a	DT	a
fibrin	NN	fibrin
matrix	NN	matrix
,	,	,
Yang	NNP	Yang
et	FW	et
al.	FW	al.
</s>
<s type="decl">
grafted	VBN	graft
heparin	NN	heparin
onto	IN	onto
fibrin	NN	fibrin
,	,	,
this	DT	this
leading	VBG	lead
to	TO	to
electrostatic	JJ	electrostatic
interactions	NNS	interaction
between	IN	between
the	DT	the
negative	JJ	negative
charges	NNS	charge
of	IN	of
heparin	NN	heparin
sulfate	NN	sulfate
groups	NNS	group
,	,	,
and	CC	and
the	DT	the
positive	JJ	positive
charges	NNS	charge
of	IN	of
BMPs	NNP	BMP
amino	NN	amino
acid	NN	acid
residues	NNS	residue
.	.	.
</s>
<s type="decl">
Interestingly	RB	Interestingly
,	,	,
heparin	NN	heparin
presence	NN	presence
slowed	VBD	slow
down	RP	down
fibrin	NN	fibrin
degradation	NN	degradation
,	,	,
and	CC	and
consequently	RB	consequently
the	DT	the
release	NN	release
of	IN	of
loaded	VBN	load
BMPs	NNP	BMP
.	.	.
</s>
<s type="decl">
Similar	JJ	Similar
observations	NNS	observation
were	VBD	be
made	VBN	make
with	IN	with
FGF	NNP	FGF
.	.	.
</s>
</p>
<p>
<s type="decl">
Despite	IN	despite
positive	JJ	positive
effects	NNS	effect
reported	VBN	report
in	IN	in
literature	NN	literature
,	,	,
there	EX	there
are	VBP	be
several	JJ	several
drawbacks	NNS	drawback
to	TO	to
fibrin	NN	fibrin
or	CC	or
growth	NN	growth
factors/proteins	NNS	factors/proteins
functionalization	NN	functionalization
.	.	.
</s>
<s type="decl">
First	RB	first
of	IN	of
all	DT	all
,	,	,
it	PRP	it
requires	VBZ	require
specific	JJ	specific
skills	NNS	skill
,	,	,
and	CC	and
it	PRP	it
is	VBZ	be
time	NN	time
consuming	VBG	consume
and	CC	and
expensive	JJ	expensive
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
proteins	NNS	protein
functionality	NN	functionality
can	MD	can
be	VB	be
altered	VBN	altered
by	IN	by
these	DT	these
modifications	NNS	modification
.	.	.
</s>
<s type="decl">
Indeed	RB	indeed
,	,	,
covalent	NN	covalent
binding	NN	binding
can	MD	can
mask	VB	mask
active	JJ	active
sites	NNS	site
,	,	,
thus	RB	thus
affecting	VBG	affect
their	PRP$	their
bioactivity	NN	bioactivity
.	.	.
</s>
<s type="sub">
As	IN	as
an	DT	an
alternative	JJ	alternative
,	,	,
non-modified	JJ	non-modified
compounds	NNS	compound
can	MD	can
be	VB	be
internalized	VBN	internalize
into	IN	into
particles	NNS	particle
,	,	,
to	TO	to
slow	VB	slow
down	RP	down
their	PRP$	their
release	NN	release
.	.	.
Wang	NNP	Wang
et	FW	et
al.	FW	al.
developed	VBD	develop
a	DT	a
sophisticated	JJ	sophisticated
system	NN	system
which	WDT	which
could	MD	could
serve	VB	serve
to	TO	to
deliver	VB	deliver
low-molecular	JJ	low-molecular
weight	NN	weight
hydrophilic	JJ	hydrophilic
drugs	NNS	drug
.	.	.
</s>
<s type="decl">
They	PRP	they
used	VBD	use
an	DT	an
antithrombosis	JJ	antithrombosis
drug	NN	drug
(	-LRB-	(
i.	FW	i.
e.	FW	e.
,	,	,
Tirofiban®	NNP	Tirofiban®
)	-RRB-	)
as	IN	as
a	DT	a
drug	NN	drug
model	NN	model
.	.	.
</s>
<s type="decl">
Drug-loaded	JJ	drug-loaded
liposomes	NNS	liposome
were	VBD	be
first	RB	first
encapsulated	VBN	encapsulate
in	IN	in
a	DT	a
fibrin	NN	fibrin
gel	NN	gel
,	,	,
and	CC	and
then	RB	then
combined	VBD	combine
to	TO	to
chitosan	NN	chitosan
.	.	.
</s>
<s type="decl">
To	TO	To
document/characterize	VB	document/characterize
the	DT	the
in	IN	in
vitro	FW	vitro
drug	NN	drug
release	NN	release
profile	NN	profile
,	,	,
different	JJ	different
parameters	NNS	parameter
were	VBD	be
studied	VBN	study
including	VBG	include
the	DT	the
surface	NN	surface
charge	NN	charge
of	IN	of
liposomes	NNS	liposome
,	,	,
the	DT	the
pore	NN	pore
size	NN	size
of	IN	of
chitosan	NN	chitosan
structure	NN	structure
,	,	,
and	CC	and
the	DT	the
crosslinking	NN	crosslinking
degree	NN	degree
of	IN	of
fibrin	NN	fibrin
gels	NNS	gel
.	.	.
</s>
<s type="decl">
All	PDT	all
these	DT	these
experimental	JJ	experimental
conditions	NNS	condition
offered	VBD	offer
different	JJ	different
prolonged	VBN	prolong
releases	NNS	release
without	IN	without
altering	VBG	alter
the	DT	the
composite	JJ	composite
bioactivity	NN	bioactivity
.	.	.
</s>
<s type="decl">
All	PDT	all
these	DT	these
modifications	NNS	modification
are	VBP	be
summarized	VBN	summarize
in	IN	in
</s>
<figure>
<s type="frag">
Figure	NN	Figure
4	CD	4
</s>
</figure>
<s type="frag">
.	.	.
</s>
</p>
</text>
